Venn Life Sciences wins €2.8m contract

Contract research organisation Venn Life Sciences said it has signed a new contract worth €2.8m with an unnamed European biotechnology client.

Venn, which provides drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients said clinical trial is a Phase II study in the area of Immunotherapeutic treatments for Multiple Sclerosis and involves patients in six countries across Europe.

The trial will start in October 2016, it added.

The company also said its Interactive Response Technology department, which centralises the randomisation of patients for Phase I to IV clinical trails and manages the logistics of these studies, has successfully qualified as a service provider to a top 10 pharmaceutical client and has been awarded an initial project involving thirty sites in China.

"This vendor qualification is a significant milestone for the IRT division and represents an exciting opportunity to grow a global account," the company said.